Review

Which of the direct acting anti-viral agents is the better drug in terms of efficacy, cost and safety, Boceprevir or Telaprevir?

Volume: 6 Number: 5 May 30, 2019
  • Mark Aziz
Medical Science and Discovery Cover
Medical Science and Discovery
PDF Download
EN

Which of the direct acting anti-viral agents is the better drug in terms of efficacy, cost and safety, Boceprevir or Telaprevir?

Abstract

Objective:  Hepatitis C virus can cause chronic hepatitis with 20-30% of those infected are developing liver cirrhosis and some developing hepatocellular carcinoma. It is a global health problem with 130-170 million people infected worldwide. The current treatment uses pegylated interferon and Ribavirin. As of 2011, two new drugs have been approved in the U.S.A and Europe, the protease inhibitors Boceprevir and Telaprevir. The aim of this structured review is to investigate which of these two new drugs is better in terms of efficacy, safety and cost. A literature search was conducted using various primary and secondary sources. A database search was conducted to find three journals for critical review.

Conclusion: The articles showed that the two drugs are equally effective and more effective than standard therapy. Boceprevir is potentially significantly cheaper. Boceprevir may also have a slightly better adverse effects profile. However, it is evident that direct clinical trials comparing the two drugs are required.

Keywords

References

  1. 1. Houghton M. Discovery of the hepatitis C virus. Liver international : official journal of the International Association for the Study of the Liver. [Historical Article Review]. 2009 Jan;29 Suppl 1:82-8.
  2. 2. Steven R. Recent advances in the molecular biology of hepatitis C virus. Journal of Molecular Biology. 2001;313(3):451-64.
  3. 3. Alter H. Discovery of non-A, non-B hepatitis and identification of its etiology. American Journal of Medicine. 1999;107(6 SUPPL. 2):16-20.
  4. 4. Houghton M. The long and winding road leading to the identification of the hepatitis C virus. Journal of hepatology. 2009;51(5):939-48.
  5. 5. Joyce MA, Tyrrell DLJ. The cell biology of hepatitis C virus. Microbes and Infection. 2010;12(4):263-71.
  6. 6. Tang H, Grisé H. Cellular and molecular biology of HCV infection and hepatitis. Clinical Science. 2009;117(2):49-65.
  7. 7. Von Hahn T, Steinmann E, Ciesek S, Pietschmann T. Know your enemy: Translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. Expert Review of Gastroenterology and Hepatology. 2010;4(1):63-79.
  8. 8. Greenwood. D SR, Peutherer. J, Barer. M. Medical Microbiology a guide to microbial infections: pathogenesis, immunity, laboratory diagnosis and control. Edinburgh ; Churchill Livingstone/Elsevier 2007.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Review

Authors

Mark Aziz This is me
United Kingdom

Publication Date

May 30, 2019

Submission Date

December 23, 2018

Acceptance Date

April 8, 2019

Published in Issue

Year 2019 Volume: 6 Number: 5

DOI

https://doi.org/10.17546/msd.501220

IZ

https://izlik.org/JA43MP62TF

Cite

RIS / Bibtex
APA
Aziz, M. (2019). Which of the direct acting anti-viral agents is the better drug in terms of efficacy, cost and safety, Boceprevir or Telaprevir? Medical Science and Discovery, 6(5), 88-95. https://doi.org/10.17546/msd.501220
AMA
1.Aziz M. Which of the direct acting anti-viral agents is the better drug in terms of efficacy, cost and safety, Boceprevir or Telaprevir? Med Sci Discov. 2019;6(5):88-95. doi:10.17546/msd.501220
Chicago
Aziz, Mark. 2019. “Which of the Direct Acting Anti-Viral Agents Is the Better Drug in Terms of Efficacy, Cost and Safety, Boceprevir or Telaprevir?”. Medical Science and Discovery 6 (5): 88-95. https://doi.org/10.17546/msd.501220.
EndNote
Aziz M (May 1, 2019) Which of the direct acting anti-viral agents is the better drug in terms of efficacy, cost and safety, Boceprevir or Telaprevir? Medical Science and Discovery 6 5 88–95.
IEEE
[1]M. Aziz, “Which of the direct acting anti-viral agents is the better drug in terms of efficacy, cost and safety, Boceprevir or Telaprevir?”, Med Sci Discov, vol. 6, no. 5, pp. 88–95, May 2019, doi: 10.17546/msd.501220.
ISNAD
Aziz, Mark. “Which of the Direct Acting Anti-Viral Agents Is the Better Drug in Terms of Efficacy, Cost and Safety, Boceprevir or Telaprevir?”. Medical Science and Discovery 6/5 (May 1, 2019): 88-95. https://doi.org/10.17546/msd.501220.
JAMA
1.Aziz M. Which of the direct acting anti-viral agents is the better drug in terms of efficacy, cost and safety, Boceprevir or Telaprevir? Med Sci Discov. 2019;6:88–95.
MLA
Aziz, Mark. “Which of the Direct Acting Anti-Viral Agents Is the Better Drug in Terms of Efficacy, Cost and Safety, Boceprevir or Telaprevir?”. Medical Science and Discovery, vol. 6, no. 5, May 2019, pp. 88-95, doi:10.17546/msd.501220.
Vancouver
1.Mark Aziz. Which of the direct acting anti-viral agents is the better drug in terms of efficacy, cost and safety, Boceprevir or Telaprevir? Med Sci Discov. 2019 May 1;6(5):88-95. doi:10.17546/msd.501220